Open AccessOsimertinib‐related liver injury with successful osimertinib rechallenge: A case report
Author(s) -
Cheng YuanLing,
Chang WeiKuo,
Yen Hao,
Peng YiJen,
Chang WeiChou,
Chang PingYing
Publication year - 2022
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.14556
Subject(s) - osimertinib , medicine , t790m , asymptomatic , lung cancer , oncology , tyrosine kinase inhibitor , liver injury , tyrosine kinase , epidermal growth factor receptor , cancer , erlotinib , gefitinib , receptor
Osimertinib is approved as the first‐line treatment for advanced non‐small cell lung cancer patients with epidermal growth factor (EGFR) mutation and for patients who develop EGFR T790M mutation during EGFR tyrosine kinase inhibitor (TKI) treatment and disease progression. Asymptomatic elevation of aminotransferase levels is commonly observed during TKI treatment; however, significant hepatotoxicity is infrequent. Here, we report a patient with osimertinib‐related drug‐induced liver injury who was successfully managed with osimertinib rechallenge.